Botulinum toxin in post-stroke patients: Stiffness modifications and clinical implications

Journal of Neurology

Volumn 251, Issue 2, 2004, Pages 189-196

  Miscio, Giacinta ^a   Del Conte, Carmen ^b   Pianca, Danilo ^b   Colombo, Roberto ^c   Panizza, Marcela ^c   Schieppati, Marco ^d   Pisano, Fabrizio ^b  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b Scientific Institute of Veruno   (Italy)

^c IRCCS   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

Botulinum toxin; Spasticity; Stiffness; Stretch reflex; Stroke

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLEXOR MUSCLE; FOREARM; HAND FUNCTION; HAND MOVEMENT; HUMAN; JOINT MOBILITY; MALE; MUSCLE FORCE; MUSCLE ISOMETRIC CONTRACTION; MUSCLE STIFFNESS; MYOTATIC REFLEX; PAIN ASSESSMENT; PASSIVE MOVEMENT; PRIORITY JOURNAL; SIDE EFFECT; SPASTICITY; STROKE; TASK PERFORMANCE; TORQUE; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADULT; AGED; ARM; BOTULINUM TOXINS; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE SPASTICITY; MUSCLE, SKELETAL; PAIN; RANGE OF MOTION, ARTICULAR; RECOVERY OF FUNCTION; REFLEX, STRETCH; TREATMENT OUTCOME; WRIST;

EID: 1242269907     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-004-0297-3     Document Type: Article

References (59)

1. Alo KM, Yland MJ, Kramer DL, Charnov JH, Redko V (1997) Botulinum toxin in the treatment of myofascial pain. Pain Clinic 10:107-116
2. Angaut-Petit D, Molgo J, Comelia JX, Faille L, Tabti N (1990) Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features. Neuroscience 37:799-808
3. Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, Benecke R, Collin C, Muller F, Ward CD, Neumann C (2000) A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 31(10):2402-2406
4. Bakheit AM, Pittock S, Moore AP, Wurker M, Otto S, Erbguth F, Coxon L (2001) A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 8(6): 559-565
5. Bedingham W, Tatton WG (1984) Dependence of EMG responses evoked by imposed wrist displacements on preexisting activity in the stretched muscles. Can J Neurol Sci 11:272-280
6. st ed. Marcel Dekker, New York, pp 557-566
7. Bhakta BB, Cozens AJ, Chamberlain MA, Bamford JM (2000) Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomized double blind controlled trial. J Neurol Neurosurg Psychiatry 69:217-221
8. Bhakta BB, Cozens JA, Bamford JM, Chamberlain MA (1996) Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 61:30-35
9. Bohannon RW, Smith MB (1987) Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 67:206-207
10. Borg-Stein J, Pine ZM, Miller JR, Brin MF (1993) Botulinum toxin for the treatment of spasticity in multiple sclerosis. Am J Phys Med Rehabil 72(6):364-368
11. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, Lee CH, Jenkins S, Turkel C (2002) Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 347(6): 395-400
12. Burbaud P, Wiart L, Dubos JL, Gaujard E, Debelleix X, Joseph PA et al. ( 1996) A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemi-paretic patients. J Neurol Neurosurg Psychiatry 61(3):265-269
13. Chapman CR, Casey K, Dubner R, Foley KM, Gracely RH, Reading AE (1985) Pain measurement: an overview. Pain 22(1):1-31
14. Comella JX, Molgo J, Faille L (1993) Sprouting of mammalian motor nerve terminals induced by in vivo injections of botulinum type D and the functional recovery of paralyzed neuromuscular junctions. Neurosci Lett 153:61-64
15. Davis EC, Barnes MP (2000) Botulinum toxin and spasticity. J Neurol Neurosurg Psychiatry 69:143-149
16. nd ed. Charles C Thomas, Springfield
17. Dengler R, Neyer U, Wolfarth K, Bettig, U, Janzik HH (1992) Local botulinum toxin in the treatment of spastic drop foot. J Neurol 239:375-378
18. Dietz V, Quintern J, Berger W (1981) Electrophysiological studies of gait in spasticity and rigidity: evidence that altered mechanical properties of muscle contribute to hypertonia. Brain 104:431-449
19. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E (1993) Botulinum toxin effects on rat jaw muscle spindles. Acta Otolaryngol (Stockh) 113:400-404
20. Flett PJ (2003) Rehabilitation of spasticity and related problems in childhood cerebral palsy. J Paediatr Child Health 39(1):6-14
21. Girlanda P, Quartarone A, Sinicopri S, Nicolosi C, Roberto ML, Picciolo G et al. (1997) Botulinum Toxin in upper limb spasticity: study of reciprocal inhibition between forearm muscles. Neuroreport 8(14):3039-3044
22. Gutman L, Pratt L (1976) Pathophysiological aspects of human botulism. Arch Neurol 33:175-179
23. Hardie RJ (2000) Botulinum toxin in muscle spasticity. J Neurol Neurosurg Psychiatry 6:689-690
24. Herman R (1970) The myotatic reflex. Clinicophysiological aspects of spasticity and contracture. Brain 93: 273-312
25. Hesse S, Lucke D, Malezic M, Bertelt C, Friedrich H, Gregoric M et al. (1994) Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiatry 57:1321-1324
26. Hufschmidt A, Mauritz KH (1985) Chronic transformation in spasticity: peripheral contribution to increased tone. J Neurol Neurosurg Psychiatry 48:676-685
27. Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, Poewe W, Wissel J, Bain P, Glickman S, Sayer A, Richardson A (2000) Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 68(6):707-121
28. Koman LA, Paterson Smith B, Balkrishnan R (2003) Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin. Paediatr Drugs 5(1):11-23
29. Lin FM, Sabbahi M (1999) Correlation of spasticity with hyperactive stretch reflexes and motor disfunction in hemiplegia. Arch Phys Med Rehab 80(5):526-530
30. Lowenthal M, Tobis JS (1957) Contractures in chronic neurologic disease. Arch Phys Med Rehabil 38:640-645
31. Mahoney FT, Barthel DW (1965) Functional evaluation: Barthel Index. Med State Med J 14:61-65
32. Manni E, Bagolini B, Pettirossi VE, Errico P (1989) Effects of botulinum toxin on extraocular muscle proprioception. Doc Ophthalmol 72(2): 189-198
33. Modugno N, Priori A, Berardelli A, Vacca L, Mercuri B, Manfredi M (1998) Botulinum toxin restores presynaptic inhibition of group Ia afferents in patients with essential tremor. Muscle Nerve 21(12):1701-1705
34. Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C et al. (1998) A double blind, randomized, parallel group study to investigate the dose equivalence of Dysport and BOTOX in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 64(1):6-12
35. Pandyan AD, Vuadens P, van Wijck FM, Stark S, Johnson GR, Barnes MP (2002) Are we underestimating the clinical efficacy of botulinum toxin (type A)? Quantifying changes in spasticity, strength and upper limb function after injections of Botox to the elbow flexors in a unilateral stroke population. Clin Rehabil 16(6):654-660
36. Panizza M, Castagna M, Di Summa A, Saibene L, Grioni G, Nilsson J (2000) Functional and clinical changes in upper limb spastic patients treated with Botulinum Toxin (BTX). Funct Neurol 15(3):147-155
37. Pierson SH, Katz DI, Tarsy D (1996) Botulinum toxin A in the treatment of spasticity: Functional Implications and Patient Selection. Arch Phys Med Rehabil 77:717-721
38. Pisano F, Miscio G, Colombo R, Pinelli P (1995) Evaluation of normal muscle tone. J Neurol Sci 135(2):168-172
39. Pisano F, Miscio G, Del Conte C, Pianca D, Candeloro E, Colombo R (2000) Quantitative measures of spasticity in post-stroke patients. Clin Neurophysiol 111:1015-1022
40. Priori A, Berardelli A, Mercuri B, Manfredi M (1995) Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearm muscles. Brain 118:801-807
41. Reddihough DS, King JA, Coleman GJ, Fosang A, McCoy AT, Thomason P, Graham HK (2002) Functional outcome of botulinum toxin A injections to the lower limbs in cerebral palsy. Dev Med Child Neurol 44(12):820-827
42. Resales RL, Arimura K, Takenaga S, Osame M (1996) Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 19(4):488-496
43. Rowland LP (2002) Stroke, spasticity, and botulinum toxin. N Engl J Med 347(6):382-383
44. Schapiro RT (2001) Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. Curr Neurol Neurosci Rep 1(3):299-302
45. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM et al. (1996) Botulinum toxin type A in the treatment of upper extremity spasticity. Neurology 46:1306-1310
46. Simpson LL (1981) The origin, structure and pharmacologic activity of botulinum toxin. Pharmacol Rev 33: 155-188
47. Simpson LL (1989) Peripheral actions of the botulinum toxin. In: Simpson LL (ed) Botulinum neurotoxin and tetanus toxin. Academic Press, San Diego (CA), pp 153-178
48. Sinkjaer T, Toft E, Larsen K, Andreassen S, Hansen HJ (1993) Non reflex and reflex mediated ankle joint stiffness in multiple sclerosis patients with spasticity. Muscle Nerve 16:69-76
49. Smith SJ, Ellis E, White S, Moore AP (2000) A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 14(1):5-13
50. Snow BJ, Tsui JK, Bhatt MH (1990) Treatment of spasticity with botulinum toxin: a double blind study. Ann Neurol 28:512-515
51. Suputtitada A (2002) Local botulinum toxin type A injections in the treatment of spastic toes. Am J Phys Med Rehabil 81(10):770-775
52. Thilmann A, Fellows SY, Ross HF (1991) Biomechanical changes at the ankle joint after stroke. J Neurol Neurosurg Psychiatry 54:134-139
53. Wade DT, Hewer RL (1987) Functional disabilities after stroke: measurement, natural and prognosis. J Neurol Neurosurg Psychiatry 50:77-82
54. Wang HC, Hsieh LF, Chi WC, Lou SM (2002) Effect of intramuscular botulinum toxin injection on upper limb spasticity in stroke patients. Am J Phys Med Rehabil 81(4):272-278
55. Wiegand H, Wellhoner HH (1977) The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex Naunyn Schmiedebergs. Arch Pharmacol 298:235-238
56. Wissel J, Muller J, Dressnandt J, Heinen F, Naumann M, Topka H et al. (2000) Management of spasticity associated pain with botulinum toxin A. J Pain Sympt Management 20(1):44-49
57. Yablon SA, Agana BT, Ivanohe CB, Boake C (1996) Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open-labeled trial. Neurology 47: 939-944
58. Yang TF, Fu CP, Kao NT, Chan RC, Chen SJ (2003) Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity. Am J Phys Med Rehabil 82(4):284-289
59. Yelnik AP, Colle FM, Bonan IV, Lamotte DR (2003) Disabling overactivity of the extensor hallucis longus after stroke: clinical expression and efficacy of botulinum toxin type A. Arch Phys Med Rehabil 84(1):147-149